Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (4946)	11/29/1997 11:21:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 17367

George, I have the printed version is a very neat piece of work. It is worthwhile to read it. Maybe your local library has it. I could fax to any who provide your fax number to my email, cacaito@bellatlantic.net I think that if they get the data evaluated by the DSMB and the results are good they will halt the trial and it could be 3 to 6 months. Of course, I am long term in this one and my next date goal is 18 month. The Lancet is UK and widely read in Europe and they use Meningoccemia. Of course, one will find many more entries with N. meningitidis in a search.

To: aknahow who wrote (4946)	12/11/1997 8:04:00 PM
From: Ellen M. Martin	Read Replies (1) \| Respond to of 17367

As you can see, I've been off-line. Went to excellent IR/disclosure conference in Las Vegas last week (Dec 3-5) and am only now catching up with my SI lurking. The Europeans and the British (who do not consider themselves Europeans for some reason) use the term "meningococcal septicemia". "Meningococcal sepsis" (!) is also in the literature (quite accurate, since the disease is a good model for rapid, fulminant sepsis), also "purpura fulminans". Happy hunting!